Nellix Inc., a Palo Alto, Calif.-based developer of an endograft for treating abdominal aortic aneurysms and thoracic aortic aneurysms, has raised $6.49 million in Series C-2 funding, according to a regulatory filing. Return backers include Essex Woodlands Health Ventures. The company has now raised around $20 million in total VC funding since 2005.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.